The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations
Clinical Cancer Research,
Clinical Article
Heon S et al. – The data show lower rates of central nervous system (CNS) progression in EGFR–mutant advanced NSCLC patients initially treated with an EGFR–TKI compared with upfront chemotherapy. If validated, the results suggest that gefitinib and erlotinib may have a role in the chemoprevention of CNS metastases from non–small cell lung cancer (NSCLC).
